ASX:PTXPrescient Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prescient Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.04 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.04Now: A$0.04▼A$0.0550-Day RangeA$0.04MA: A$0.04▼A$0.0452-Week RangeA$0.02Now: A$0.04▼A$0.15Volume537,831 shsAverage VolumeN/AMarket Capitalization$17.35 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesOptions Chain Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Prescient Therapeutics. Previous Next 2.8 Community Rank Outperform VotesPrescient Therapeutics has received 18 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrescient Therapeutics has received 14 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrescient Therapeutics has received 56.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Prescient Therapeutics and other stocks. Vote “Outperform” if you believe PTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrescient Therapeutics does not currently pay a dividend.Dividend GrowthPrescient Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prescient Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prescient Therapeutics are expected to decrease by -100.00% in the coming year, from A$0.01 to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prescient Therapeutics is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prescient Therapeutics is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrescient Therapeutics has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:PTX Previous Symbol CUSIPN/A CIKN/A Webwww.ptxtherapeutics.com Phone61 3 9692 7222Debt Debt-to-Equity RatioN/A Current Ratio15.64 Quick Ratio15.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio6.10 P/E GrowthN/A Sales & Book Value Annual Sales$1.54 million Price / Sales11.29 Cash FlowA$0.02 per share Price / Cash Flow1.91 Book ValueA$0.03 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares394,260,992Market Cap$17.35 million Next Earnings DateN/A OptionableOptionable Receive PTX News and Ratings via Email Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter. Prescient Therapeutics (ASX:PTX) Frequently Asked Questions How has Prescient Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Prescient Therapeutics' stock was trading at A$0.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PTX shares have increased by 25.7% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus. Has Prescient Therapeutics been receiving favorable news coverage? News stories about PTX stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Prescient Therapeutics earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Prescient Therapeutics. Who are some of Prescient Therapeutics' key competitors? Some companies that are related to Prescient Therapeutics include Pediapharm (PDP), Biotron (BIT), Cohbar (CWBR), Promis Neurosciences (PMN), Sirona Biochem (SBM), Immutep (IMM), e-Therapeutics (ETX), Oxford Biodynamics (OBD), Navidea Biopharmaceuticals (NAVB), Synairgen (SNG), Aerpio Pharmaceuticals (ARPO), Mereo BioPharma Group (MPH), Medlab Clinical (MDC), Equillium (EQ) and Verona Pharma (VRP). View all competitors. What other stocks do shareholders of Prescient Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SKYCITY Entertainment Group (SKC) and Finders Resources (FND). Who are Prescient Therapeutics' key executives? Prescient Therapeutics' management team includes the following people: Mr. Yatomi-Clarke Steven Lee, MD, CEO & DirectorProf. Said M. Sebti M.D., Chief Scientific OfficerDr. Terrence G. Chew M.D., R.A.C., Chief Medical Officer (Age 72)Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)Dr. Claudia Gregorio-King, VP of Operations What is Prescient Therapeutics' stock symbol? Prescient Therapeutics trades on the ASX under the ticker symbol "PTX." What is Prescient Therapeutics' stock price today? One share of PTX stock can currently be purchased for approximately A$0.04. How big of a company is Prescient Therapeutics? Prescient Therapeutics has a market capitalization of $17.35 million and generates $1.54 million in revenue each year. What is Prescient Therapeutics' official website? The official website for Prescient Therapeutics is www.ptxtherapeutics.com. How can I contact Prescient Therapeutics? The company can be reached via phone at 61 3 9692 7222. This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
